Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 9:12:1447173.
doi: 10.3389/fped.2024.1447173. eCollection 2024.

In-utero exposure to tenofovir disoproxil fumarate pre-exposure prophylaxis and growth metrics in HIV unexposed breastfed infants in South Africa: a post hoc analysis of the CAP 016 PrEP in pregnancy RCT

Megeshinee Naidoo  1 , Kimesh L Naidoo  2 , Carl Lombard  3   4 , Alicia C Desmond  1 , Richard Clark  5 , James F Rooney  5 , Glenda Gray  6 , Dhayendre Moodley  1   7
Affiliations

In-utero exposure to tenofovir disoproxil fumarate pre-exposure prophylaxis and growth metrics in HIV unexposed breastfed infants in South Africa: a post hoc analysis of the CAP 016 PrEP in pregnancy RCT

Megeshinee Naidoo et al. Front Pediatr. .

Abstract

Objective: We evaluated growth metrics in HIV unexposed African breastfed infants in the first 18 months of life in association with in-utero exposure to Tenofovir Diphosphate Fumarate (TDF) containing pre-exposure prophylaxis (PrEP).

Design: We conducted a secondary data analysis of a TDF-PrEP randomized control trial (CAP016 RCT). Pregnant women without HIV were randomized to initiating TDF-PrEP in pregnancy (Immediate-PrEP-IP) or deferred initiation of TDF-PrEP at cessation of breastfeeding (Deferred-PrEP-DP).

Methods: Infant weight (W), length (L), and head circumference (HC) were measured at birth and 6, 26, 50, and 74 weeks of age. Stored dried blood spot samples from pregnant women randomized to the IP arm were used to measure tenofovir-diphosphate (TFV-DP) levels. Age-stratified mean weight-for-age (WAZ), length-for-age (LAZ), weight-for-length (WLZ), and head circumference-for-age (HCAZ) Z-scores were compared between infants exposed to varying TFV-DP concentrations and infants in the DP arm.

Results: A total of 455 mother-infant pairs were included in the secondary analysis, 228 in the IP arm and 227 in the DP arm. WAZ, LAZ, WLZ, and HCAZ scores were comparable between infants in the Deferred-PrEP arm and Immediate-PrEP arm. In a mixed-effects linear regression model adjusting for maternal age, body mass index, socioeconomic and newborn characteristics, in-utero exposure to varying TFV-DP levels was not associated with WAZ (β = -0.52), LAZ (β = -0.46), WLZ (β = -0.43) and HCAZ (β = -0.11) scores over time.

Conclusion: There was no evidence of an association between growth metrics in the first 18 months of life and in-utero exposure to TFV-DP among breastfed HIV unexposed infants.

Keywords: breastfeeding; exposure; growth; in-utero; preexposure prophylaxis (PrEP).

PubMed Disclaimer

Conflict of interest statement

JR and RC are employed by Gilead Sciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Consort diagram of Infant Assessments by Randomisation Arm.
Figure 2
Figure 2
Mean weight-for-age, length-for-age, weight-for-length and head circumference-for-age Z-score from 6 t0 74 weeks by prEP exposure and in-utero TFV-DP concentration exposure.
See this image and copyright information in PMC

References

    1. Thomson KA, Baeten JM, Mugo NR, Bekker LG, Celum CL, Heffron R. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women. Curr Opin HIV AIDS. (2016) 11(1):18–26. 10.1097/COH.0000000000000207 - DOI - PMC - PubMed
    1. Kinuthia J, Pintye J, Abuna F, Mugwanya KK, Lagat H, Onyango D, et al. PrEP implementation for young women and adolescents (PrIYA) programme. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. (2020) 7(1):e38–48. 10.1016/S2352-3018(19)30335-2 - DOI - PMC - PubMed
    1. Joseph Davey DL, Bekker LG, Gorbach PM, Coates TJ, Myer L. Delivering preexposure prophylaxis to pregnant and breastfeeding women in Sub-Saharan Africa: the implementation science frontier. AIDS. (2017) 31(16):2193–7. 10.1097/QAD.0000000000001604 - DOI - PMC - PubMed
    1. WHO Technical brief. Preventing HIV During Pregnancy and Breastfeeding in the Context of pre-Exposure Prophylaxis (PrEP). Geneva: World Health Organization; (2017).
    1. Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. (2015) 16(8):502–11. 10.1111/hiv.12252 - DOI - PMC - PubMed

LinkOut - more resources